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Summary The anti-mitotic drug vindesine was coupled chemically to a monoclonal antibody raised originally
against the human osteogenic sarcoma cell line, 791T. The cytotoxicity of the conjugate in vitro was tested, in
comparison with free vindesine, against sarcoma 791T and other antigenically cross-reactive osteogenic
sarcoma-cell lines, and also against tumour cell lines which have no detectable reaction with the monoclonal
antibody. Continuous exposure of cultured 791T cells indicated that the vindesine was partially inactivated
following conjugation since the conjugate was less toxic than the free drug. However, antibody-binding
activity was essentially preserved following conjugation. Despite diminished drug activity in the conjugate,
assays designed to mimic antibody binding to tumour in which target cells were treated with conjugate and
washed before culture, showed selective cytotoxicity for osteogenic sarcoma lines with little or no effect on
non-cross reactive control cells. In comparison, free vindesine was toxic equally for all cell lines and free
antibody was non-toxic. These studies indicate that conjugation of a cytotoxic agent to a monoclonal
antibody can confer on that agent selectivity for a particular target cell type which is recognised by the
antibody.
The use of monoclonal antibodies for targeting
therapeutic agents to tumours is currently a major
area of interest in tumour immunology (Baldwin et
al., 1981). In essence, the aim is to produce
conjugates of antibody and a toxic agent which
would localise selectively at the tumour site, and
thereby exert maximum damage to the tumour cells
while minimising effects on normal tissues. Most
attention has been focused on the use of plant or
bacterial toxins such as the A-chain of ricin, abrin,
gelonin, or the A-chain of Diphtheria toxin
(Blythman et al., 1981; Gilliland, et al., 1980;
Krolick et al., 1980; Trowbridge & Domingo, 1981;
Thorpe & Ross, 1982). These molecules alone are
relatively non-toxic, but when combined with an
antibody in such a way that they become bound to
target cells they become internalised, leading to
death of the cell. It has been estimated that a single
molecule of such toxins entering the cell could
result in cell death, so that this approach could be
potentially effective against cells having a low
antigen density (Eiklid et al., 1980; Yamaizumi et
al., 1978). For this reason, the antibody portion of
the conjugate would need to be highly specific for
the tumour, and not react against any, normal cells
which are necessary for subsequent survival of the
host. In practice, many monoclonal antibodies
hitherto believed to be specific for certain tumours
are now known to react also against some sub-
populations of normal cells, and it may be
unrealistic to expect absolute tumour specificity.
A safer alternative to plant toxins is to use
conventional anti-cancer drugs which are already
acceptable for clinical practice. The use of
adriamycin coupled to a monoclonal antibody has
already been reported to have therapeutic effects
against a rat mammary carcinoma (Pimm et al.,
1982b). Conjugates of the phase-specific anti-mitotic
agent vindesine and polyclonal antibodies have
been described previously and been shown in vitro
to have cytotoxic effects on human tumour cells
(Johnson et al., 1982). In this study we report the
selective action against certain tumour target cells
of vindesine coupled to a monoclonal antibody
raised against an osteogenic sarcoma cell line.
Materials and methods
Target cells Target cells used in these studies are
listed in the Table. All cell lines were grown as
monolayers in Eagle's Minimum Essential Medium
(MEM) supplemented with 10% newborn calf serum
(10% NCS), and were passaged routinely after
detachment with 0.25% trypsin +0.02% EDTA.
Monoclonal antibody The antibody, designated
a791T/36, was obtained from a hybridoma
produced by fusing spleen cells from a mouse
immunised against osteogenic sarcoma line 791T,
with the P3-NS1-Ag- 4 mouse myeloma (Embleton
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et al., 1981). This monoclonal antibody is an IgG2b
which reacts preferentially with tumour cells rather
than normal cells, but is not absolutely specific for
osteogenic sarcoma cells. Its reactivity with target
cells used in the present study is summarized in
the Table.
Vindesine-monoclonal antibody conjugate Anti-
791T/36 antibody was isolated from ascitic fluid by
adsorption onto immobilised Protein A-Sepharose
(Pharmacia) at pH8 and 40C, and subsequent
elution with 0.1 M citrate/phosphate buffer (pH 3.5).
The eluate was neutralised, dialysed against water,
lyophilised and reconstituted at 20mgml-' in
0.34M borate buffer (pH 8.6) for conjugation. Two
conjugates were prepared and purified as described
previously (Johnson et al., 1982, Rowland et al.,
1981). The conjugates were characterised
spectroscopically as containing (a) 44 ugml -1
vindesine (VDS) and 1.33mgml-' a791T/36 Ig at a
ratio of 6.5 moles VDS/mole Ig, and (b) 49pgml-
VDS and 1.54mgml-1 a791T/36 Ig at a ratio of 6.1
moles VDS/mole Ig.
Cytotoxicity tests Target cells were harvested with
trypsin + EDTA mixture and were repeatedly
pipetted with a Pasteur pipette to ensure a
suspension of single cells. The cells were washed
and resuspended in MEM +10% NCS and aliquots
of 105 cells were spun down in plastic centrifuge
tubes (Sterilin). The pellet was resuspended in 200yl
phosphate-buffered saline (pH 7.2, PBS), or in
200 1il of various dilutions of vindesine (VDS),
antibody (a791T/36) or VDS-ax791T/36 conjugate.
The cells were incubated for 15min at 37°C and
then centrifuged. The supernatant was removed and
the cells were washed once in 2ml MEM +10%
NCS, followed by final resuspension in 2ml MEM
+ 10% NCS. Aliquots of 200p (containing 104
cells) were plated in flat-bottom tissue culture
Microtiter plates (Sterilin M29 ART) using at least
4 wells/sample. The cells were cultured for 24h at
37°C, then 50pl of MEM +10% CS containing
O.1,uCi of "Se-selenomethionine was added to each
well. Samples of the labelled methionine were also
added to 200 u1 MEM + 10% NCS in wells
containing no cells, to control for non-specific
adsorption. The cells were incubated for a further
16h. The supernatant was removed and the cells
were washed 3x in PBS, with visual monitoring
before and after washing to ensure that cells were
not lost during the process. The plates were dried
down and sprayed with a plastic sealing film
(Nobecutane) and individual wells were separated
with a band saw for counting in a y spectrometer.
Incorporation of "Se by treated cells was
expressed as a percentage of the incorporation in
controls (i.e. cells pretreated with PBS).
Selenomethionine incorporation correlated
extremely well with cell numbers determined
visually, and thus provided an objective
measurement of cell survival and growth.
Competitive inhibition of antibody
binding Antibody activity of VDS-a791T/36
conjugates was assessed by competitive inhibition of
binding of fluorescein isothiocyanate (FITC-
labelled oc791T/36 to 791T osteogenic sarcoma cells.
Conjugate was mixed with 500ng FITC-labelled
a791T/36 in proportions of 4:1, 2:1, 1:1, 1:2 and 1:4
in terms of ng of IgG protein. For comparative
purposes unconjugated antibody was also mixed
with FITC-labelled antibody in the same
proportions. Aliquots of 2 x I05 791T cells were
incubated for 30min at room temperature with the
mixtures, then washed 3 x with PBS. Cell
fluorescence due to bound FITC was then measured
on a Becton Dickinson FACS IV flow
cytofluorimeter. Mean fluorescence intensity was
plotted as the mean channel number of excitation
profiles.
Results
Preliminary toxicity tests in which 791T osteogenic
sarcoma cells were incubated for 24h in the
presence of VDS or VDS--o791T/36 conjugate
before labelling with 75Se-selenomethionine showed
that incorporation was 50% inhibited by ,
lOngml-1 of VDS and 20ugml-1 of conjugate
(Figure 1). This indicates that under the conditions
of the tests the drug was rendered 2,000-fold less
active following conjugation to antibody. Antibody-
binding activity, however, was not affected to a
significant degree. Antibody in the conjugate was
shown to compete effectively with FITC-labelled
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Figure 1 Survival of 79IT osteogenic sarcoma cells
cultured continuously for 24h with Vindesine (VDS)
or VDS--o791T/36 monoclonal antibody conjugate
(VDS-MoAb). Vertical bars indicate s.e.
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antibody by flow cytometry of treated 791T cells
(Figure 2), the level of competition corresponding
closely to that predicted from the proportions of
conjugate and FITC-labelled antibody and only
slightly less than obtained with unconjugated
antibody.
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Figure 2 Competitive inhibition of binding of FITC-
labelled a79lT/36 monoclonal antibody (FITC-MoAb)
to 791T osteogenic sarcoma cells by VDS-a791T/36
conjugate(VDS-MoAb)(solid columns) orunconjugated
a79lT/36 (MoAb) (open columns), assayed by flow
cytometry.
Table Reactivity of a791T/36 monoclonal antibody
against cultured human tumour cells
No. antibody molecules
Cell line Tumour type bound per cell*
791T Osteogenic sarcomat 22 x 105
788T Osteogenic sarcomat 16 x 105
2 OS Osteogenic sarcomat 5.3 x 105
T278 Osteogenic sarcomat 5.1 x 105
RPMI
5966 Melanoma <2 x 104
Mel-57 Melanoma <2 x 104
PA-I Ovarian carcinoma <2 x 104
T24 Bladder carcinoma <2 x 104
*Determined according to Fazekas de St. Groth (1979).
t791T and 788T osteogenic sarcoma cells were obtained
from the U.S. Naval Biomedical Center, Oakland, Ca, by
arrangement with Dr W.A. Nelson-Rees; 2 OS and T278
cells were obtained from Dr H. Strander.
Antibody binding to 791T cells reaches almost
plateau level within 15min at 37°C (R.A. Robins,
personal communication) but continued exposure to
VDS, either in free or conjugated form, resulted in
non-specific uptake (not due to antibody binding)
so it was necessary to use a pretreatment assay to
detect target cell specificity. VDS was much less
toxic when cells were pre-exposed to it for 15min,
followed by 24h culture, than when they were
cultured for 24h in the continuous presence of the
drug. This reduction of toxicity was at least 1,000-
fold. Accordingly, the toxicity of VDS and VDS-
a791T/36 conjugate were compared on a series of
cell lines whose reactivity with a791T/36 was known
(Table), following exposure to the agent for 15min
before cultivation (see Materials and Methods).
Purified a791T/36 antibody alone was
simultaneously tested on cell lines known to bind it.
Effects on 4 osteogenic sarcoma cell lines of
conjugate, and free drug and antibody at
concentrations equivalent to those in the conjugate,
are shown in Figure 3. The antibody alone had no
significant effect on any of the 4 lines (791T, 788T, 2
OS and T278) even though it binds to these cells
and is cytotoxic in the presence of added rabbit
complement (Price et al., submitted for publication).
VDS-a791T/36 conjugate was toxic for all 4 cell
lines. In the case of 791T, 2 OS, and T278 it was
more toxic than VDS alone, and with 788T it was
less toxic, but in all cases cytotoxicity was highly
significant at doses of 10igml-' VDS or greater
(P<0.001 by Student's test). Complete cytotoxicity
was not achieved, presumably because not all target
cells entered mitosis during the assay.
Figure 4 depicts a comparison between the effects
of VDS and the drug-antibody conjugate on 4 cell
lines (PAl, T24, Mel-57 and RPMI 5966) which do
not react with the antibody. The conjugate had no
significant effect on the non-crossreactive cells, even
at the highest concentrations tested. VDS alone,
however, was as toxic for these cells as it was for
the osteogenic sarcomas. Tests on non-reactive cells
were performed simultaneously with those on
antibody-binding osteogenic sarcomas thus
excluding any possibility that toxicity of conjugate
for the latter cells was due to free VDS. These
experiments clearly show that although the free
drug was not discriminatory, the conjugate was
selectively toxic for cells which react with the
antibody.
Discussion
The selective effect of vindesine coupled to
a791T/36 monoclonal antibody resides in the fact
that the conjugate was able to bind to the target46 M.J. EMBLETON et al.
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Figure 3 Relative effects of VDS, VDS-a791T/36 conjugate (VDS-MoAb) and a791T/36 (MoAb) on
osteogenic sarcoma cell lines. (a) 791T target cells, (b) 788T cells, (c) 2 OS cells, and (d) T278 cells. 75Se uptake
is expressed as a percentage relative to that in PBS controls. Vertical bars indicate s.e. The s.e. at far right
(100%) is that obtained in PBS controls. The concentrations of VDS and MoAb indicated are in ng ml- . All
cell lines depicted bind the a791T/36 antibody (Table).
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Figure 4 Relative effects of VDS and VDS-a791T/36 conjugate (VDS-MoAb) on cell lines which do not bind
a791T/36 antibody. (a) Melanoma Mel-57, (b) melanoma RPMI 5966, (c) ovarian carcinoma PA-1, and (d)
bladder carcinoma T24. 7'Se uptake is expressed as a percentage relative to that in PBS controls. Vertical
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cell surface by antibody-antigen interaction.
Toxicity of the conjugate was perhaps due to entry
into cells during the subsequent culture period.
However, from previous studies with radiolabelled
antibody and target cells (Baldwin et al., 1981) it is
evident that saturation of the binding sites was
achieved with much lower levels of antibody than
those required to produce cyotoxicity by the
conjugate. In the present experiments with
conjugate, at the LD50 for 791T cells there were the
equivalent of 1011 VDS molecules and 1.5 x 1010
antibody molecules per cell. It is possible that entry
of the conjugate takes place during the 15min pre-
incubation period, but only at super-saturating
levels.
In previous studies using a vindesine-polyclonal
anti-CEA conjugate (Johnson et al., 1982; Rowland
et al., 1981), it was found that a lung carcinoma cell
line was much less susceptible to free vindesine than
to conjugate. The present study shows no such
difference; indeed free vindesine was somewhat more
active. This contrast between the two studies cannot
be readily explained, but may reflect differences in
susceptibility of the cell lines used or may relate to
the different properties of a monoclonal and a
polyclonal antibody as a carrier.
Although it is difficult to predict the success of in
vivo anti-tumour therapy on the basis of in vitro
results, the above suggests that if VDS-a791T/36
could bind to tumour cells in vivo, then some anti-
tumour response could be expected. It has been
shown that radio-iodinated a791T/36 antibody
localises specifically to xenografts of 791T, 788T 2
OS and T278 in immune-deprived mice (Pimm et
al., 1982a) so tumour localisation and binding of
the drug-antibody conjugate would be likely to
occur following parenteral injection. Since VDS is
cytotoxic for cells in mitosis, where it disrupts
formation of the mitotic spindle, it is likely to affect
only cells regularly entering mitosis. In the case of
xenografts it is possible that most cells fall into this
category, but cells which are normally dormant and
enter the mitotic subsequent to eradication of a
portion of the tumour population could be
subjected to a further treatment of the host with
drug-antibody conjugate, if necessary.
Although repeated administration of murine
monoclonal antibodies to patients might produce an
anti-mouse Ig response, recent clinical studies (Sears
et al., 1982; Miller et al., 1982) suggest that
problems such as anaphylaxis can be avoided. If
human monoclonals with suitable specificities
become available (Baldwin et al., 1981) some of the
immune response problems should be eliminated.
However, the drug portion of a conjugate may still
act as an immunological hapten.
The main action of vindesine is as a phase-
specific anti-mitotic agent. As such, when coupled
to antibody, it offers a potential advantage over
antibody-plant toxin conjugates which could kill
any non-dividing cell binding the conjugate through
antigenic cross-reactivity. Moreover, VDS is already
in use clinically and its side-effects are considered to
be tolerable.
It is not clear to what extent damage to the drug
following chemical coupling would affect
therapeutic efficacy of the conjugate. Although the
drug could be expected to be less effective directly if
administered at normal dosage, binding of the
conjugate at the tumour site might counteract the
loss of activity. In this case better conjugation
methods, resulting in greater preservation of drug
activity, could greatly enhance anti-tumour therapy.
These questions can only be answered by in vivo
experiments, and these are now being initiated using
VDS-a791T/36 conjugate and xenografts arising
from osteogenic sarcoma lines in immune-deprived
mice.
M.J.E., E.J., and R.W.B., were supported by the Cancer
Research Campaign, London, U.K.
We thank Mr C. Smith for help in purifying
monoclonal antibody.
References
BALDWIN, R.W., EMBLETON, M.J. & PRICE, M.R. (1981).
Monoclonal antibodies specifying tumour-associated
antigens and their potential for therapy. Molec.
Aspects Med, 4, 329.
BLYTHMAN, H.E., CASELLAS, P., GROS, 0. & 5 others
(1981). Immunotoxins: Hybrid molecules ofmonoclonal
antibodies and a toxin subunit specifically kill tumour
cells. Nature, 290, 145.
EIKLID, K., OLSNES, S. & PIHL, A., (1980). Entry of lethal
doses of abrin, ricin and modeccin into the cytosol of
Hela cells. Exp. Cell Res., 126, 321.
EMBLETON, M.J., GUNN, B., BYERS, V.S., and BALDWIN,
R.W. (1981). Antitumor reactions of monoclonal
antibody against a human osteogenic sarcoma cell line,
Br. J. Cancer, 43, 582.
FAZEKAS DE ST. GROTH, S., (1979). 'The quality of
antibodies and cellular receptors', In Immunological
Methods, (Ed. Lefkovits & Perris) New York,
Academic Press, p.l.
GILLILAND, D.G., STEPLEWSKI, Z., COLLIER, R.J.,
MITCHELL, K.F., CHANG, T.H., and KOPROWSKI, H.
(1980). Antibody-directed cytotoxic agents: Use of
monoclonal antibody to direct the action of toxin A-
chains to colorectal carcinoma cells. Proc. Nat. Acad.
Sci. 77, 4539.CYTOTOXICITY BY VINDESINE-ANTIBODY CONJUGATE 49
JOHNSON, J.R., FORD, C.H.J., NEWMAN, C.E.,
WOODHOUSE, C.S., ROWLAND, G.F., and SIMMONDS,
R.G. (1982). A vindesine anti-CEA conjugate cytotoxic
for human cancer cells in vitro. Br. J.Cancer, 44, 472.
KROLICK, K.A., VILLIMEZ, C., ISAKSON, P., UHR, J.W.,
and VITETTA, E.S. (1980). Selective killing of normal or
neoplastic B-cells by antibodies coupled to the A-chain
of ricin. Proc. Nat. Acad. Sci., 77, 5419.
MILLER, R.A., MALONEY, D.G., WARNKE, R. and LEVY,
R. (1982). Treatment of B-cell lymphoma with
monoclonal anti-idiotype antibody. N. Eng. J. ofMed.
306, 517.
PIMM, M.V., EMBLETON, M.J., PERKINS, A.C. & 4 others
(1982). In vivo localisation of anti-osteogenic sarcoma
791T monoclonal antibody in osteogenic sarcoma
xenografts. Int. J. Cancer, 30, 75.
PIMM, M.V., JONES, J.A., PRICE, M.R., MIDDLE, J.G.,
EMBLETON, M.J., and BALDWIN, R.B. (1982b).
Tumour localisation of monoclonal antibody against a
rat mammary carcinoma and suppression of tumour
growth with Adriamycin-antibody conjugates. Cancer
Immunol. Immunother, 12, 125.
PRICE, M.R., PIMM, M.V., & BALDWIN, R.W. (1982).
Complement-dependent cytotoxicity of anti-human
osteogenic sarcoma monoclonal antibodies. Br. J.
Cancer, 46, 4.
ROWLAND, G.F., SIMMONDS, R.G., CORVALAN, J.R.F. &
5 others (1981). the potential use of monoclonal
antibodies in drug targeting. Protides Biol. Fluids, 29,
921.
SEARS, H.F., ATKINSON, B., MATTIS, J. & 5 others. (1982).
Phase-l clinical trial of monoclonal antibody in
treatment of gastrointestinal tumours. Lancet, i, 762.
THORPE, P.E., & ROSS, W.C.J. (1982). The preparation and
cytotoxic properties of antibody-toxin conjugates.
Immunol. Revs, 62, 119.
TROWBRIDGE, I.S., & DOMINGO, D.L. (1981). Anti-
transferrin receptor monoclonal antibody and toxin-
antibody conjugates affect growth of human tumour
cells. Nature, 294, 171.
YAMAIZUMI, M., MEKADA, E., UCHIDA, T. & OKADA, Y.
(1978). One molecule of diphtheria toxin fragment A
introduced into a cell can kill the cell. Cell, 15, 245.